Vassiliki Economides
Director of Finance/CFO bei GRITSTONE BIO, INC.
Vermögen: 585 348 $ am 31.03.2024
Profil
Vassiliki Celia Economides currently works at Altum Pharmaceuticals, Inc., as Director and Gritstone bio, Inc., as Chief Financial Officer & Executive Vice President from 2021.
Ms. Economides also formerly worked at BioMarin Pharmaceutical, Inc., as Director-Global Medical Affairs from 2015 to 2016, Biotechnology Innovation Organization, as Director-Investor Relations & Program Development, Prosensa Holding NV, as Senior Director-IR & Corporate Communications, Aurinia Pharmaceuticals, Inc., as Vice President-Corporate & Public Affairs, and Kezar Life Sciences, Inc., as Senior Vice President-Strategy & External Affairs.
Ms. Economides received her graduate degree in 2004 from The Trustees of Columbia University in The City of New York and undergraduate degree in 2001 from McGill University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GRITSTONE BIO, INC.
0,23% | 01.02.2024 | 227 762 ( 0,23% ) | 585 348 $ | 31.03.2024 |
Aktive Positionen von Vassiliki Economides
| Unternehmen | Position | Beginn |
|---|---|---|
| GRITSTONE BIO, INC. | Director of Finance/CFO | 23.06.2021 |
Altum Pharmaceuticals, Inc.
 Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | Director/Board Member | - |
Ehemalige bekannte Positionen von Vassiliki Economides
| Unternehmen | Position | Ende |
|---|---|---|
| AURINIA PHARMACEUTICALS INC. | Investor Relations Contact | 01.03.2019 |
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.06.2016 |
| KEZAR LIFE SCIENCES, INC. | Investor Relations Contact | - |
| PROSENSA HOLDING NV | Investor Relations Contact | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Investor Relations Contact | - |
Ausbildung von Vassiliki Economides
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| McGill University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| KEZAR LIFE SCIENCES, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Prosensa Holding NV
 Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
